US · Healthcare · Biotechnology
EPS came in at -1.24 against a street estimate of -1.16 — a miss of 6.9%.
Analysts rate Forte Biosciences Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $73.80.
| Fund | Stake |
|---|---|
| Federated Hermes Inc | 8.62% |
| Fred Alger Management, LLC | 6.22% |
| Orbimed Advisors, LLC | 5.84% |
| HHG PLC | 5.80% |
| Affinity Asset Advisors, LLC | 4.94% |
| MPM Oncology Impact Management LP | 4.89% |
| Adage Capital Partners Gp LLC | 4.64% |
| Vanguard Capital Management, LLC | 2.60% |
| Document | Date |
|---|---|
| Material agreement · Q3 2026 | 2026-07-27 |
| Reg FD disclosure · Q3 2026 | 2026-07-09 |
| Board / officer change · Q2 2026 | 2026-06-02 |
| Results announced · Q2 2026 | 2026-05-14 |
| Quarterly report · Q1 2026 | 2026-05-11 |
| Proxy statement · Q2 2026 | 2026-04-29 |
| Annual report FY2025 | 2026-03-31 |
| Quarterly report · Q3 2025 | 2025-11-14 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Forte Biosciences Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.